title: PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells.
abstract: Neuroendocrine tumors, although rare, are currently diagnosed with increasing frequency, owing to improved imaging techniques and a greater clinical awareness of this condition. To date, BON is a very well established and characterized human pancreatic neuroendocrine tumor cell line used to study the signal transduction and genetic regulation of neuroendocrine tumors secretion and growth. The secretory activity of BON cells is known to release peptides, such as chromogranin A, neurotensin, and biogenic amines, as 5-HT, permitting an assessment of their biological activity. The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP), released from the enteric neurons in the gastrointestinal tract by binding to its high affinity receptor PAC1, has been previously shown to regulate the secretory activity and growth of the neuroendocrine-derived enterochromaffin-like cells in the stomach. This led us to speculate that PACAP might also play an important role in regulating the growth of human neuroendocrine tumors. Accordingly, in the current study, we have shown that BON cells express PAC1 receptors, which are rapidly internalized upon PACAP activation. Furthermore, PAC1 receptor activation, in BON cells, couple to intracellular Ca(2+) as well as cAMP responses and induce the release of intracellular 5-HT, activate mitogen activated protein kinases, and stimulate cellular growth. These data indicate that PACAP functionally can stimulate 5-HT release and promote the growth of the BON neuroendocrine tumor cell line. Therefore, PACAP and its receptors regulate neuroendocrine tumor secretory activity and growth in vivo, and this knowledge will permit the development of novel diagnostic and therapeutic targets for managing neuroendocrine tumors in humans.
authors.affiliation: Department of Medicine, University of California, CURE Digestive Diseases Research Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA. pgermano@ucla.edu
authors.forename: Patrizia M
authors.initials: PM
authors.lastname: Germano
authors.forename: Sandy N
authors.initials: SN
authors.lastname: Lieu
authors.forename: Janjing
authors.initials: J
authors.lastname: Xue
authors.forename: Helen J
authors.initials: HJ
authors.lastname: Cooke
authors.forename: Fievos L
authors.initials: FL
authors.lastname: Christofi
authors.forename: Yuxin
authors.initials: Y
authors.lastname: Lu
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Pisegna
mesh_terms: D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology; D018278:Carcinoma, Neuroendocrine / Q000378:metabolism* / Q000503:physiopathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004705:Endocytosis / Q000502:physiology; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000502:physiology; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000378:metabolism* / Q000494:pharmacology; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
chemical_list: D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D012701:Serotonin
references.citation: J Clin Invest. 2001 Oct;108(7):1051-9
references.pmid: 11581306
references.citation: Pancreas. 1994 Jan;9(1):83-90
references.pmid: 8108375
references.citation: World J Surg. 1996 Feb;20(2):126-31
references.pmid: 8661807
references.citation: Life Sci. 2002 Jun 28;71(6):667-78
references.pmid: 12072155
references.citation: Peptides. 1990 Nov-Dec;11(6):1205-9
references.pmid: 1965032
references.citation: N Engl J Med. 1986 May 1;314(18):1145-51
references.pmid: 3007986
references.citation: Regul Pept. 2002 Nov 15;109(1-3):135-40
references.pmid: 12409225
references.citation: Regul Pept. 2002 May 30;105(3):145-54
references.pmid: 11959368
references.citation: Endocrinology. 1990 Jul;127(1):272-7
references.pmid: 2361473
references.citation: Oncogene. 2005 Feb 10;24(7):1284-9
references.pmid: 15580291
references.citation: Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6345-9
references.pmid: 8392197
references.citation: Ann N Y Acad Sci. 2004 Apr;1014:179-88
references.pmid: 15153433
references.citation: Ann N Y Acad Sci. 1998 Dec 11;865:100-10
references.pmid: 9928002
references.citation: Br J Cancer. 2005 Apr 25;92(8):1506-16
references.pmid: 15846300
references.citation: Biochem Biophys Res Commun. 1990 Jul 31;170(2):643-8
references.pmid: 2383262
references.citation: Neuron. 1992 Apr;8(4):811-9
references.pmid: 1314625
references.citation: Acta Oncol. 1989;28(3):341-6
references.pmid: 2663047
references.citation: Cancer Res. 1995 Nov 1;55(21):4886-91
references.pmid: 7585525
references.citation: J Mol Neurosci. 2004;22(1-2):83-92
references.pmid: 14742913
references.citation: J Cell Physiol. 1992 Jan;150(1):1-7
references.pmid: 1309821
references.citation: Nature. 1993 Sep 9;365(6442):170-5
references.pmid: 8396727
references.citation: J Clin Invest. 1999 Nov;104(10):1383-91
references.pmid: 10562300
references.citation: Anal Biochem. 1974 Apr;58(2):541-8
references.pmid: 4827395
references.citation: J Biol Chem. 1996 Jul 19;271(29):17267-74
references.pmid: 8663363
references.citation: Ann N Y Acad Sci. 2002 Oct;971:544-6
references.pmid: 12438180
references.citation: Endocrinology. 1994 Jan;134(1):315-23
references.pmid: 7903932
references.citation: Ann N Y Acad Sci. 1994 Sep 15;733:1-17
references.pmid: 7978856
references.citation: Regul Pept. 2002 Nov 15;109(1-3):115-25
references.pmid: 12409223
references.citation: J Neurosci Methods. 2003 Oct 30;129(2):169-81
references.pmid: 14511819
references.citation: Am J Physiol Cell Physiol. 2002 Feb;282(2):C374-82
references.pmid: 11788349
references.citation: Am J Physiol Gastrointest Liver Physiol. 2002 Nov;283(5):G1197-206
references.pmid: 12381534
references.citation: Regul Pept. 1994 Aug 31;53(1):17-29
references.pmid: 7800856
references.citation: Br J Cancer. 2003 Nov 3;89(9):1766-75
references.pmid: 14583782
references.citation: J Biol Chem. 2004 Jul 2;279(27):28466-74
references.pmid: 15123666
references.citation: Annu Rev Immunol. 1999;17:331-67
references.pmid: 10358762
references.citation: QJM. 1998 Dec;91(12):795-8
references.pmid: 10024944
references.citation: FEBS Lett. 1993 Nov 8;334(1):3-8
references.pmid: 8224221
references.citation: Biochem Biophys Res Commun. 1999 Nov 30;265(3):752-7
references.pmid: 10600492
references.citation: Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G245-54
references.pmid: 12851216
references.citation: J Biol Chem. 2003 Jan 17;278(3):1663-70
references.pmid: 12429744
references.citation: Pharmacol Rev. 1998 Jun;50(2):265-70
references.pmid: 9647867
references.citation: Acta Oncol. 1993;32(2):125-30
references.pmid: 8323753
references.citation: Endocrinology. 1995 May;136(5):2252-61
references.pmid: 7720675
references.citation: Peptides. 1993 Mar-Apr;14(2):241-6
references.pmid: 8387187
references.citation: Gastroenterology. 2001 Dec;121(6):1400-6
references.pmid: 11729119
references.citation: Peptides. 2001 Jun;22(6):861-6
references.pmid: 11390014
references.citation: J Biol Chem. 2000 Nov 17;275(46):36134-42
references.pmid: 10908567
references.citation: Breast Cancer Res Treat. 1999 Jul;56(2):177-86
references.pmid: 10573110